Atossa Therapeutics (ATOS) announced the appointment of Dr. Arezoo Mirad as Senior Medical Director. Prior to joining Atossa, Dr. Mirad served as Medical Director for Corcept Therapeutics (CORT).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATOS:
- Atossa announces full enrollment of Phase 2 Karisma-Endoxifen trial
- Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
- Atossa Therapeutics reports Q3 EPS (5c), consensus (7c)
- Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Atossa Therapeutics, Inc. (ATOS) Q3 Earnings Cheat Sheet